Here's the link to the S-1: http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=7097172
CNBI:
China Baicaotang is engaged in pharmaceutical distribution, pharmacy retailing, and the manufacture of pharmaceuticals and medical-related products through its subsidiaries Guangxi Liuzhou Baicaotang Medicine Limited, Hefeng Pharmaceutical Co. Limited, and Guangxi Liuzhou Baicaotang Medicine Retail Limited in Guangxi province, China. It operates the largest regional retail network in Guangxi province, consisting of 66 directly owned retail stores in Guangxi province and currently over 8,000 products are distributed through the Company's wholesale distribution network.
For more information, please contact:
Company Contact:
Ms. Shelly Zhang, Chief Financial Officer
China Baicaotang Medicine Limited
Email: z_shelly@hotmail.com
Tel: +86-772-363-8318
Investor Relations Contact:
Mr. Shaun Smolarz, Financial Writer
Email: shaun.smolarz@ccgir.com
Tel: +1-646-701-7444
Mr. Crocker Coulson, President
Email: crocker.coulson@ccgir.com
Tel: +1-646-213-1915
CCG Investor Relations
Web: http://www.ccgirasia.com
Just saw they recently filed an S-1. Their financials are impressive:
Sales Revenue:
Year ended:
06 - 32M
07 - 66M
08 - 109M
Nine mos. ended Sep. 30:
08 - 86M
09 - 99M
So I'm guessing year ended 09 revenues will come in at around 120M.
Net Income:
Year ended
06 - 2M
07 - 6M
08 - 17M
Nine mos. ended Sep. 30
08 - 14M
09 - 15M
So I'm guessing year ended 09 net income will come in at around 18M.
Cash:
Year ended
06 - 143k
07 - 520k
08 - 1.3M
As of Sep. 30, 2009:
13M (Yes, you are reading that correctly.)
Total Assets:
Year ended
06 - 32M
07 - 44M
08 - 66M
As of Sep. 30, 2009:
89M
Total Liabilities:
Year ended
06 - 24M
07 - 32M
08 - 37M
As of Sep. 30, 2009:
45M (I'd have liked to see this figure not be this high by only Sep.)
Ratio of Assets/Liabilities:
06 - 1.3
07 - 1.4
08 - 1.8
As of Sep. 30, 2009:
2 (So even though the liabilities were increasing at a greater rate by Sep. 30, 2009 than they were for the years 2006-2008, the assets are still increasing at a proportionately higher rate in relation the the liabilities, which makes up for in the increasing liabilities.)
Outstanding Shares - as of 3/1/10
38,154,340
Outstanding Shares (Fully Diluted - assuming all warrants are exercised):
40,265,575
Authorized Shares:
100,000,000
EPS as of Sep. 30, 2009:
.36 (To make things easy, we'll assume they earned .48 for the entire year).
Today's P/E using assumed TTM EPS of .48:
5.5
Free Level II Quotes:
http://www.otcmarkets.com/pink/quote/quote.jsp?symbol= style='background-color:yellow;'>cnbi
Recent News:
2/23/10 - China Baicaotang Retains CCG Investor Relations
http://finance.yahoo.com/news/China-Baicaotang-Retains-CCG-prnews-3985708260.html?x=0&.v=17
3/3/10 - China Baicaotang to Attend Rodman & Renshaw Annual China Investment Conference
http://finance.yahoo.com/news/China-Baicaotang-to-Attend-prnews-1313888732.html?x=0&.v=77
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM